- Condition: Hemophilia A
Interventions: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method; Biological: PEGylated Recombinant Factor VIII
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation; Baxter Innovations GmbH
Recruiting - verified May 2012 - Condition: Facial Rhytides
Intervention:
Sponsors: Allergan; Allergan
Not yet recruiting - verified May 2012 - Condition: Chronic Idiopathic Constipation
Interventions: Drug: KWA-0711; Drug: Placebo
Sponsors: Kissei Pharmaceutical Co., Ltd.; Kissei Pharmaceutical Co., Ltd.
Recruiting - verified May 2012 - Condition: Clear Cell Renal Carcinoma
Interventions: Drug: Axitinib; Drug: Placebo
Sponsors: SFJ Pharmaceuticals, Inc.; SFJ Pharmaceuticals, Inc.; Pfizer
Recruiting - verified May 2012 - Condition: Kawasaki Disease Refractory to Initial Therapy With Intravenous Immunoglobulin
Interventions: Drug: TA-650; Drug: Polyethylene Glycol-treated Human Immunoglobulin (VGIH)
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified May 2012 - Condition: Extravasations of Anthracycline Anti-cancer Agents
Intervention: Drug: Dexrazoxane
Sponsors: Kissei Pharmaceutical Co., Ltd.; Kissei Pharmaceutical Co., Ltd.
Recruiting - verified May 2012 - Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nintedanib low dose; Drug: Nintedanib medium dose; Drug: Nintedanib medium dose; Drug: Nintedanib high dose; Drug: Nintedanib high dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: S-488410
Sponsors: Shiga University; Shiga University; Showa University; Fukushima Medical University; Tohoku University; Shionogi
Recruiting - verified May 2012 - Condition: Cognitive Impairment
Intervention: Dietary Supplement: green tea powder
Sponsors: University of Shizuoka; University of Shizuoka
Not yet recruiting - verified April 2012 - Condition: Hypertension With Renal Dysfunction
Intervention: Drug: LCZ696
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified May 2012 - Condition: Dupuytren's Contracture
Intervention: Drug: Collagenase Clostridium Histolyticum
Sponsors: Asahi Kasei Pharma Corporation; Asahi Kasei Pharma Corporation
Not yet recruiting - verified April 2012 - Condition: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Drug: CAZ-AVI; Drug: Doripenem; Drug: Either 500 mg of Ciprofloxacin (oral); Drug: or 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
Sponsors: AstraZeneca; AstraZeneca; Cerexa, Inc.
Not yet recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Sitagliptin; Drug: Alogliptin; Drug: Vildagliptin
Sponsors: Nagaoka Red Cross Hospital; Nagaoka Red Cross Hospital; Kurume University
Not yet recruiting - verified April 2012 - Condition: Pediatric Ulcerative Colitis
Intervention: Drug: TA-650
Sponsors: Mitsubishi Tanabe Pharma Corporation; Mitsubishi Tanabe Pharma Corporation
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dulaglutide; Drug: Insulin glargine; Drug: Sulfonylureas (SU); Drug: Biguanide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsors: Erasmus Medical Center; Erasmus Medical Center
Recruiting - verified May 2012 - Condition: Brain Ischemia
Intervention: Drug: Rivaroxaban(Xarelto_ BAY59-7939)
Sponsors: Bayer; Bayer
Not yet recruiting - verified April 2012 - Condition: Brain Ischemia
Intervention: Drug: Rivaroxaban (Xarelto_ BAY59-7939)
Sponsors: Bayer; Bayer
Not yet recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI10773; Drug: BI10773; Drug: BI10773; Drug: BI10773
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012

Clinical Trial Locations 